Longitudinal assessment of hepatocellular carcinoma response to stereotactic body radiation using gadoxetate-enhanced MRI: a case series

[1]  Zhijun Mai,et al.  Response evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: magnetic resonance imaging findings , 2023, Abdominal Radiology.

[2]  G. Giannelli,et al.  Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review , 2023, International journal of molecular sciences.

[3]  E. Moshier,et al.  Characterization and Predication of Signal Changes in Normal Liver Parenchyma on Gadoxetic Acid Enhanced Magnetic Resonance Imaging After Liver Directed Radiation Therapy. , 2021, International journal of radiation oncology, biology, physics.

[4]  M. Westerhoff,et al.  LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy with Radiologic-Pathologic Explant Correlation in patients with SBRT treated hepatocellular carcinoma. , 2021, International journal of radiation oncology, biology, physics.

[5]  Silvia D. Chang,et al.  SBRT for HCC: Overview of technique and treatment response assessment , 2021, Abdominal Radiology.

[6]  T. Kim,et al.  Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation , 2020, Abdominal Radiology.

[7]  M. Schipper,et al.  Natural history of hepatocellular carcinoma after stereotactic body radiation therapy , 2020, Abdominal Radiology.

[8]  L. Xing,et al.  Potential of Gd-EOB-DTPA as an imaging biomarker for liver injury estimation after radiation therapy. , 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.

[9]  Prasad R. Shankar,et al.  Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up. , 2019, International journal of radiation oncology, biology, physics.

[10]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[11]  J. Babb,et al.  Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology. , 2017, Journal of hepatology.

[12]  H. Hussain,et al.  Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. , 2017, International journal of radiation oncology, biology, physics.

[13]  J. Salleron,et al.  Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma , 2017, PloS one.

[14]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[15]  S. Venkatesh,et al.  Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review , 2016, Abdominal Radiology.

[16]  Ahmedin Jemal,et al.  Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer , 2016, Cancer.

[17]  F. Miller,et al.  Hepatic imaging following intra-arterial embolotherapy , 2016, Abdominal Radiology.

[18]  K. Awai,et al.  Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma , 2015, Japanese Journal of Radiology.

[19]  B. Siewert,et al.  CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors , 2015, Gastroenterology research and practice.

[20]  F. Yin,et al.  Stereotactic body radiotherapy: A critical review for nonradiation oncologists , 2014, Cancer.

[21]  S. Park,et al.  Stereotactic Body Radiotherapy-Induced Arterial Hypervascularity of Non-Tumorous Hepatic Parenchyma in Patients with Hepatocellular Carcinoma: Potential Pitfalls in Tumor Response Evaluation on Multiphase Computed Tomography , 2014, PloS one.

[22]  Zahra Kassam,et al.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Perkins,et al.  Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma , 2012, Cancer.

[24]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[25]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[26]  Kathryn J Fowler,et al.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm , 2017, Abdominal Radiology.

[27]  W. Franklin,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.